ArticleFrontiers in oncology2023
The innovative model based on artificial intelligence algorithms to predict recurrence risk of patients with postoperative breast cancer.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Exploring the role of artificial intelligence in chemotherapy development, cancer diagnosis, and treatment: present achievements and future outlook.Frontiers in oncology · 2025Pooled it
- AI Trustworthiness in the Perioperative Period for Patients with Serious Illness: Scoping Narrative Review.JMIR perioperative medicine · 2026Article
- External validation of a data-driven algorithm to identify breast cancer recurrences from administrative healthcare data.Breast (Edinburgh, Scotland) · 2026Article
- SCAR-Net-assisted ultrasound diagnosis of postoperative scars and recurrent lesions in breast cancer.iScience · 2026Article
- Applications of Artificial Intelligence (AI) in Breast Cancer Care Delivery and Education: A Scoping Review.International journal of environmental research and public health · 2026Article
- Identification of Prognostic Factors in Esophageal Cancer Using Machine Learning: A Retrospective Study Based on the SEER Database.Journal of clinical medicine · 2026Article
- Balancing global standards and regional nuances in breast cancer care: the role of guidelines, clinical research, precision medicine, and artificial intelligence in advancing quality of care for patients worldwide.Cancer biology & medicine · 2026Article
- Lung cancer intravasation-on-a-chip: Visualization and machine learning-assisted automatic quantification.Bioactive materials · 2025Article
- Review
- Article
- Harnessing artificial intelligence for predicting breast cancer recurrence: a systematic review of clinical and imaging data.Discover oncology · 2025Review
- Leveraging survival analysis and machine learning for accurate prediction of breast cancer recurrence and metastasis.Scientific reports · 2025Article
- Artificial Intelligence in Breast Cancer Diagnosis and Surgical Decision-Making: An Updated and Comprehensive Overview of Precision and Personalization in Current Evidence.Cancer management and research · 2025Review
- Role of AI in empowering and redefining the oncology care landscape: perspective from a developing nation.Frontiers in digital health · 2025Review
- A Hybrid Algorithm of ML and XAI to Prevent Breast Cancer: A Strategy to Support Decision Making.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop a machine learning model to retrospectively study and predict the recurrence risk of breast cancer patients after surgery by extracting the clinicopathological features of tumors from unstructured clinical electronic health record (EHR) data. Methods: This retrospective cohort included 1,841 breast cancer patients who underwent surgical treatment. To extract the principal features associated with recurrence risk, the clinical notes and histopathology reports of patients were collected and feature engineering was used. Predictive models were next conducted based on this important information. All algorithms were implemented using Python software. The accuracy of prediction models was further verified in the test cohort. The area under the curve (AUC), precision, recall, and F1 score were adopted to evaluate the performance of each model. Results: A training cohort with 1,289 patients and a test cohort with 552 patients were recruited. From 2011 to 2019, a total of 1,841 textual reports were included. For the prediction of recurrence risk, both LSTM, XGBoost, and SVM had favorable accuracies of 0.89, 0.86, and 0.78. The AUC values of the micro-average ROC curve corresponding to LSTM, XGBoost, and SVM were 0.98 ± 0.01, 0.97 ± 0.03, and 0.92 ± 0.06. Especially the LSTM model achieved superior execution than other models. The accuracy, F1 score, macro-avg F1 score (0.87), and weighted-avg F1 score (0.89) of the LSTM model produced higher values. All Conclusions: The constructed model accurately predicted the recurrence risk of breast cancer patients from EHR data and certainly evaluated the chemoresistance and prognosis of patients. Therefore, our model can help clinicians to formulate the individualized management of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.